CRL · 8-K · 20260805PR000115

Acquisition / Partnership / Divestiture

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 71 · Surprise 60 · In source text

Charles River completed the divestitures of certain European Discovery Services sites and its CDMO and Cell Solutions businesses in May 2026. The CDMO and Cell Solutions transactions produced a second-quarter loss of $63.7 million, or $1.40 per share, and a six-month net divestiture loss of $181.7 million. Six-month proceeds from the sale of businesses and assets were $176.6 million, while the company also recorded a $38.5 million gain on the sale of certain Wilmington, Massachusetts assets. The divestitures contributed 3.8 percentage points to reported company revenue growth, including 9.6 points for Manufacturing Solutions and 2.5 points for DSA.

Key facts

• Within Schedule 5, the gain (loss) on divestitures for three months ended June 27, 2026 primarily reflects a $63.7 million loss on the CDMO and Cell Solutions divestiture and a $0.3 million gain on the European Discovery Divestiture. source
• Recorded a net loss related to the CDMO and Cell Solutions divestiture totaling $63.7 million, or $1.40 per share, which principally drove the GAAP net loss. source
• Completed divestitures in May 2026 of certain European Discovery Services sites and the CDMO and Cell Solutions businesses. source
• Collaborated with Arovella Therapeutics to provide in vitro Next Generation Sequencing (NGS) services added through the PathoQuest acquisition. source
• Net cash used in investing activities for six months ended June 27, 2026: $(379,748) thousand, including acquisition of businesses and assets, net of cash acquired of $(467,254) thousand. source
• Proceeds from sale of businesses and assets, net: $176,563 thousand in six months ended June 27, 2026. source

Impact estimates